Prof. John Marshall (Ruesch Center for the Cure of Gastrointestinal Cancer, and, Georgetown University Hospital, Washington, DC, USA) joins us to discuss the major highlights neuroendocrine cancers presented at ASCO 2022. Prof. Marshall discusses new findings from the ECOG-ACRIN E2211 trial, which showed the longest progression-free survival and highest response rates with temozolomide plus capecitabine reported to date for patients with pancreatic neuroendocrine tumours (0:40), and other important highlights in neuroendocrine cancers.
The abstract entitled: A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: Final analysis of efficacy and evaluation of MGMT (ECOG-ACRIN E2211) presented by Dr Pamela L. Kunz, at the ASCO annual meeting, June 3-7, 2022.
Disclosures: John Marshall is consultant for, and has received honoraria/honorarium from, Bayer, Caris, Indivumed, Merck and Pfizer. He is a Speaker’s Bureau participant with Bayer, Caris, Merck and Pfizer.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.
Filmed in coverage of the 2022 American Society of Clinical Oncology (ASCO) annual meeting.
